加速慢性淋巴细胞白血病 - - 波兰成人白血病研究小组的特征和回顾性分析
Oktawia Sośnia1, Elżbieta Iskierka-Jażdżewska2,3, Anna Puła2,4,5
1Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
概括
加速慢性淋巴细胞白血病 (A-CLL) 的预后比典型的CLL更差. 基于fludarabine的疗法和向治疗改善了A-CLL患者的生存结果,超过了R-CHOP协议.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 加速慢性淋巴细胞白血病 (A-CLL) 是一种罕见的CLL变体.
- A-CLL的特点是具有侵略性的临床表现和较差的预后.
研究的目的:
- 为了研究A-CLL患者的特征.
- 为了评估A-CLL的治疗结果.
主要方法:
- 在波兰 (2013-2023) 治疗的106名A-CLL患者的回顾性分析.
- 总生存时间 (OS) 和无进展生存时间 (PFS) 的分析.
主要成果:
- 在未接受治疗的A-CLL中,中位数的生存期为6.05年;中位数的PFS为5.66年.
- 与更糟糕的PFS相关的因素包括ECOG> 2和del17p.
- 与R-CHOP协议相比,基于fludarabine的疗法显著改善了OS和PFS.
结论:
- 甲型CLL的预后比典型的CLL更差.
- 基于fludarabine的疗法和向疗法是A-CLL的有效治疗选择.
- 对于A-CLL,R-CHOP协议的有效性较低.
相关概念视频
Disorders of Leukocytes
720
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
720
Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K


